Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05496738 · ClinicalTrials.gov registry record · Phase 1
A Preliminary Study to Evaluate PF-07264660 in Healthy Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT05496738 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 59 participants.
The verdict
NCT05496738, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of study medicine PF-07264660 compared to a placebo. This is the first study of PF-07264660 in humans. All participants in this study will received PF-07264660 or a placebo and it will be assigned by chance. People may be able to participate if they are healthy. The study medicine may be given by shots under the skin or through a vein depending on which group you are assigned to. If you are assigned into Part A, you will receive the study medicine once, stay overnight at the research unit from 3 to 5 overnight stays and you will need to visit the clinic about 11 follow-up visits. Participants will be in this study for up to about 541 days. If you are assigned into Part B, you will receive the study medicine three times, stay overnight at the clinic from 3 to 5 overnight stays and you will need to visit the research unit about 12 follow-up visits. Participants willbe in this study for up to about 561 days.
Interventions
- DRUG PF-07264660 intravenous single ascending dose
- DRUG PF-07264660 subcutaneous multiple ascending dose
- OTHER Intravenous placebo
- OTHER subcutaneous placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2022-08-16 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05496738
The ClinicalTrials.gov registry entry for NCT05496738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which PF-07264660 intravenous single ascending dose is the first listed.
NCT05496738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05496738 about?
NCT05496738 is a clinical study titled "A Preliminary Study to Evaluate PF-07264660 in Healthy Participants". The purpose of this clinical trial is to learn about the safety and effects of study medicine PF-07264660 compared to a placebo. This is the first study of PF-07264660 in humans. All participants in this study will received PF-07264660 or a placebo and it will be assigned by chance. People may be ab...
What is the current status of trial NCT05496738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2022-08-16. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT05496738?
The interventions under investigation include: PF-07264660 intravenous single ascending dose (DRUG), PF-07264660 subcutaneous multiple ascending dose (DRUG), Intravenous placebo (OTHER), subcutaneous placebo (OTHER).
Who is sponsoring clinical trial NCT05496738?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.